Skip to main content
TipRanks
Go Ultimate75% OFF

Pacira Pharmaceuticals (82P) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

82P Analyst Ratings

Hold
7Ratings
0Buy7Hold0Sell
Based on 7 analysts giving stock ratings to Pacira Pharmaceuticals in the past 3 months

82P Stock 12 Month Forecast

CHF30.60▲(0.00% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Pacira Pharmaceuticals in the last 3 months. The average price target is CHF 30.60 with a high forecast of CHF 30.67 and a low forecast of CHF 30.25. The average price target represents a ― change from the last price of ―.
Highest Price TargetCHF30.67Average Price TargetCHF30.60Lowest Price TargetCHF30.25

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for CH:82P
Price TargetArticle
J.P. MorganCHF19.33→CHF30.67hold―Upgraded10/12/26
Truist FinancialCHF26.05→CHF30.67hold―Downgraded10/09/26
H.C. WainwrightCHF31.93→CHF30.67hold―Downgraded10/09/26
Leerink PartnersCHF23.53→CHF30.67hold―Reiterated10/09/26
Needham―hold―Downgraded10/08/26
JefferiesCHF30.25hold―Downgraded10/08/26
RBC CapitalCHF21.01→CHF30.67hold―Assigned10/08/26
BarclaysCHF21.01hold―Reiterated08/17/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
OVIDOvid Therapeutics
PTGXProtagonist Therapeutics
IMUXImmunic
IVAInventiva
PALIPalisade Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pacira Pharmaceuticals

3 Months
Success Rate1/3 ratings generated profit
33%
Average Return
-2.13%

Copying xAi Drug Manufacturers - Specialty and Generic's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -2.13% per trade.

1 Year
Success Rate1/2 ratings generated profit
50%
Average Return
+19.90%

Copying Google Drug Manufacturers - Specialty and Generic's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +19.90% per trade.

2 Years
Success Rate1/2 ratings generated profit
50%
Average Return
+19.90%

Copying Google Drug Manufacturers - Specialty and Generic's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +19.90% per trade.

82P Analyst Recommendation Trends

05101520Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for 82P
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy22210
Buy45663
Hold1231211
Sell01110
Strong Sell00000
total710122014

In the current month, 82P has received 3 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. 82P average Analyst price target in the past 3 months is 30.60.

82P Financial Forecast

CHF-1CHF-0.5CHF0CHF0.5CHF1Q1 2026Q3 2026Q4 2026
ConsensusCHF0.59

82P Earnings Forecast

Next quarter’s earnings estimate for 82P is CHF 0.59 with a range of ― to ―. The previous quarter’s EPS was CHF 0.59. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

CHF148.5MCHF152.7MCHF156.9MCHF161.2MCHF165.4MQ1 2026Q3 2026Q4 2026
ConsensusCHF148M

82P Sales Forecast

Next quarter’s sales forecast for 82P is CHF 148.45M with a range of ― to ―. The previous quarter’s sales results were CHF 148.45M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

82P Stock Forecast FAQ

What is CH:82P’s average 12-month price target, according to analysts?
Based on analyst ratings, Pacira Pharmaceuticals’s 12-month average price target is CHF30.60.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Pacira Pharmaceuticals a Buy, Sell or Hold?
Pacira Pharmaceuticals has a consensus rating of Hold, which is based on 0 buy ratings, 7 hold ratings and 0 sell ratings.
What is Pacira Pharmaceuticals’s share price target?
The average share price target for Pacira Pharmaceuticals is CHF30.60. This is based on 7 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF30.67, and the lowest forecast is CHF30.25. The average share price target represents a 0.00% increase from the current price of ―.
What do analysts say about Pacira Pharmaceuticals?
Pacira Pharmaceuticals’s analyst rating consensus is a Hold. This is based on the ratings of 7 Wall Street analysts.
How can I buy shares of Pacira Pharmaceuticals?
To buy shares of CH:82P, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.